For an ordinary investor, the most useful number in biotech is rarely a trial result. It is how long the money lasts. The one company in our dossier with a full run of audited-style figures is Incyte Corporation, and its cash history shows how much a biotech balance sheet can move. Incyte held $3,213,376,000 in cash at the end of fiscal 20231, $1,687,829,000 at the end of fiscal 20241, and $3,097,817,000 at the end of fiscal 20251. Those are SEC-filing figures that Via News has verified.
Incyte: a balance sheet that breathes
The quarterly figures show the same swings. At the end of Q2 2024 Incyte held $987,293,0001. A year later, in Q2 2025, it held $1,954,969,0001. In Q2 2026 it held $3,982,375,0001, the highest reading in our set. In Q3 2026 it held $3,275,881,0001, so cash fell between the last two quarters. The third-quarter readings for each year tell a similar story: $3,227,230,000 in 2023, $1,304,109,000 in 2024, $2,455,006,000 in 2025 and $3,275,881,000 in 20261.
The filings give the amounts but not the reasons. We cannot say from this data whether the movements reflect deals, milestone payments, share buybacks or timing. Nor does the dossier give Incyte's total market value, so we cannot tell you what share of the company its cash represents. What the series does show is that a cash balance is a snapshot, and a sharp drop in a single year, as in fiscal 2024, is not necessarily a sign of distress when the next year recovers.
The cost side is steadier. Incyte's cost of revenue, the direct cost of producing what it sells, was $254,990,000 in fiscal 2023, $312,068,000 in fiscal 2024 and $372,130,000 in fiscal 20252. In the latest quarter, Q3 2026, it was $108,744,000, against $99,001,000 in Q3 20252. Capital expenditure was $48,700,000 in both fiscal 2024 and fiscal 20253. The two years carry an identical figure, which can happen but is worth a second look before anyone builds a model on it. Earnings per share for fiscal 2023 was $2.654. The dossier holds no later EPS, so we make no claim about current profitability.
On the pipeline side, our entity records show Incyte developing a treatment for PD-1 Resistant Head and Neck Cancer5. Our research summary also notes Incyte presenting pancreatic cancer combinations at ESMO. That detail rests on the topic summary rather than on a document we hold, so treat it as unverified.
Smaller companies: the runway is the story
Incyte can fund itself. Clinical-stage companies often cannot, and for them the question is how long cash lasts against the date of the next data. Scribe Therapeutics is a clear case. In its Q3 2026 report, dated 12 November 2026, the company said it is listed on the Nasdaq Global Market under the ticker SCTX and has raised capital to fund the initial clinical development of STX-1150, STX-1200 and STX-14006. It also said enrolment continues in the first-in-human Phase 1 trial of STX-1150, with initial clinical data expected in the first half of 20276. Our research summary puts Scribe's cash at $174.2 million. The excerpt of the release we hold does not show that figure, so we flag it as coming from our own summary and not from a checked document. The release also says Scribe expanded its collaboration with Sanofi6.
The commercial case Scribe makes is about adherence. It says current LDL-C lowering therapies are limited by poor persistence, with studies showing 50% to 70% of patients discontinue treatment within one year6. It adds that people with naturally occurring PCSK9 loss-of-function variants have been reported to have 28% lower mean LDL-C and up to 88% lower coronary heart disease risk, and that STX-1150 aims to mimic that protection6. These are the company's own statements. A first-half 2027 data readout is the next test of whether any of it holds.
Vor Bio offers the opposite kind of evidence, a finished trial. Its final two-year Phase 3 TELIGAN results for telitacicept in IgA nephropathy, announced 22 October 2026, showed an annualised eGFR slope of -0.6 against -5.7 mL/min/1.73 m² per year for placebo, a difference of 5.1 (p<0.001)7. It also reported 89% and 81% reductions in the risk of confirmed eGFR declines of at least 30% and at least 40%, with a favourable safety profile7. That is the kind of result that tends to make later financing easier. It is still the company's own release.
Akari Therapeutics sits earlier on the curve. Its CEO describes its payload strategy as moving AKTX-101 toward planned Phase 1 development in mid-20278. The company says ADC-refractory patients are "a significant, growing unmet need" and an exclusive opportunity for its novel payload, which current and most future ADCs will not be able to access8. A first-in-human trial roughly eight months away means Akari will be raising and spending well before it has clinical data.
The market they are raising into
Biotechs do not set their own funding conditions. Our event log records a $1 trillion tech selloff on 30 October 2026 that deepened fears of an AI bubble, with the Nasdaq 100 having its worst day since June9. The next day OpenAI cut its funding target by $10 billion9. On 1 November, Binance users withdrew $3.6 billion when the exchange reopened after a hack9. The Binance event has a security cause, so we do not claim it is part of the same story. Taken together, the first two events suggest investors are becoming more selective.
Via News's analysis is that this matters to biotech because the sector now borrows part of its story from AI. Funding for a company that says it uses AI in discovery tends to be judged alongside funding for AI itself. The dossier cannot prove that link: it contains no biotech financing data from the weeks after the selloff. It is a reasoned inference, not a measured result.
The commercial side shows what a finished product earns
The contrast with approved products is large. Eisai's partner reporting put global Leqembi sales at JPY 29.3 billion in Q2 202610. That produced a royalty to BioArctic of SEK 179 million, which BioArctic says is "an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025"10. The comparison is distorted by a one-time stockpiling effect in China of around JPY 5.3 billion in Q2 2025. Excluding it, BioArctic says "royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year"10. Our entity records show BioArctic as partnered with Eisai11. For a small company, a royalty is cash that does not depend on a funding window staying open, which is why it matters so much to the runway question above.
The AI claims, and how far to trust them
The AI element of this theme is the weakest-sourced. Radical Numerics says AI-designed viruses have treated its first patient, in an experimental treatment targeting drug-resistant E. coli12. Generation Lab says its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues"13. Both claims reached us through MIT Technology Review items. On our measurements, only 6% of 16 checked claims from that source held up12,13, a very small sample, so the figure is a warning and not a verdict. The Generation Lab statement comes from a company fact sheet quoted by the journalist13. It is marketing language, not evidence. Neither claim should figure in a valuation.
Source quality across the rest of the dossier is mixed too. The press-release feed behind the Scribe, Vor, Akari and BioArctic items held up on 54% of 6,752 checked claims6,7,8,10. That is a measured track record, and it argues for reading the primary documents and for treating company statements as claims, not facts. A Motley Fool comparison of AbbVie and Eli Lilly held up on 31% of 58 checked claims, so we did not use it.
What to watch
- Scribe's first STX-1150 data in the first half of 2027, and how the company funds itself until then6.
- Akari's move to a Phase 1 trial in mid-20278.
- Incyte's next filing, to see whether cash recovers from its Q3 2026 level of $3,275,881,000 or keeps falling1.
- Any sign that the late-October tech weakness reaches biotech funding. Our dossier does not yet show it.
Sources:
1 Via News verified data: Incyte Corporation cash, SEC filing (FY 2023 to Q3 2026)
2 Via News verified data: Incyte Corporation cost of revenue, SEC filing (FY 2023 to Q3 2026)
3 Via News verified data: Incyte Corporation capex, SEC filing (FY 2024 and FY 2025)
4 Via News verified data: Incyte Corporation EPS, SEC filing (FY 2023)
5 Via News entity graph: Incyte Corporation develops PD-1 Resistant Head and Neck Cancer
6 NewsEOD, "Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights" (2026-11-12)
7 NewsEOD, "Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy" (2026-10-22)
8 NewsEOD, "Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner" (2026-10-15)
9 Via News event log: $1 trillion tech selloff (2026-10-30); OpenAI cuts funding target (2026-10-31); Binance users withdraw $3.6 billion (2026-11-01)
10 NewsEOD, "Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026" (2026-07-29)
11 Via News entity graph: BioArctic AB (publ) partnered with Eisai Co., Ltd.
12 MIT Technology Review, "The Download: computing’s next leap and permafrost’s climate threat" (undated)
13 MIT Technology Review, "A startup claims it’s found a drug to make your blood young" (undated)

